David C. Hastings

Companies

• Trevi Therapeutics, Inc.Chief financial officer Jan 12, 2026 to now¹
• SCYNEXIS INCBoard member Sep 28, 2015 to now²
• Arbutus BiopharmaChief financial officer Jun 21, 2018 to Feb 19, 2025³
• Notable Labs, Ltd.Board member Jan 3, 2023 to Jan 3, 2023⁴
• Entasis TherapeuticsBoard member Sep 25, 2018 to Jul 11, 2022⁵
• IncyteChief financial officer Jan 17, 2006 to Jun 6, 2014⁶

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• Arbutus Biopharma ABUS249,824 shares⁷$1.1M at $4.29Feb 14, 2025
• SSCYNEXIS INC SCYX11,522 shares⁸$42.9K at $3.72Jun 26, 2026
• ETEntasis Therapeutics0 shares⁹Jul 11, 2022

As of each latest filing. The line shows shares held over time.

Recent filings

• Jun 26, 2026Granted 2,875 shares of SCYNEXIS INC⁸
• Jun 26, 2025Granted 23,000 shares of SCYNEXIS INC¹⁰
• Feb 14, 2025Granted 90,100 shares of Arbutus Biopharma⁷
• Feb 4, 2025Sold 22,183 shares at $3.28 of Arbutus Biopharma¹¹
• Jun 20, 2024Granted 23,000 shares of SCYNEXIS INC¹²
• Feb 2, 2024Sold 9,593 shares at $2.31 of Arbutus Biopharma¹³
• Feb 1, 2024Granted 112,500 shares of Arbutus Biopharma¹³
• Jun 15, 2023Granted 10,000 shares of SCYNEXIS INC¹⁴
• Feb 1, 2023Granted 79,000 shares of Arbutus Biopharma¹⁵
• Jul 11, 2022Returned to company 27,500 shares at $2.20 of Entasis Therapeutics⁹
• Jul 7, 2022U 22,000 shares at $2.20 of Entasis Therapeutics⁹
• Jun 17, 2022Granted 10,000 shares of SCYNEXIS INC¹⁶
• Jan 18, 2022Granted 27,500 shares of Entasis Therapeutics¹⁷